Financial Performance - The company expects a net profit loss of between -58 million to -75 million yuan for the year 2025, representing a decline of 110.21% to 171.83% compared to the same period last year[3]. - The net profit attributable to shareholders is projected to be between -76 million to -59 million yuan, a decrease of 109.10% to 169.34% year-over-year[3]. Cost and Margin Analysis - The decline in gross margin is attributed to slight decreases in market prices of certain products and higher unit costs due to new projects not fully releasing capacity[5]. - Interest expenses have risen due to the cessation of capitalizing interest on convertible bonds and project-specific loans after the completion of investment projects[6]. Research and Development - Increased R&D expenses are a result of the company's commitment to "innovation-driven development" and enhanced collaboration in research and development[5]. - The company has introduced new products in 2025, which have higher initial production costs[5]. Reporting and Auditing - The specific financial data for 2025 will be detailed in the annual report, which has not yet been audited[7].
共同药业(300966) - 2025 Q4 - 年度业绩预告